Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.

Nuray Aktay Ayaz Serife Gül Karadag Rahime Koç Fatma Gül Demirkan Figen Cakmak Hafize Emine Sönmez

Published in: Rheumatology international (2020)

TCZ is an effective treatment option in JIA and switching from IV to SC route when necessary is found to be an effective and acceptable alternative by the patients as well.

Keyphrases

juvenile idiopathic arthritis
patient satisfaction
disease activity
end stage renal disease
rheumatoid arthritis
newly diagnosed
randomized controlled trial
ejection fraction
chronic kidney disease
systematic review
high dose
prognostic factors
rheumatoid arthritis patients
low dose